| Code | CSB-RA856887MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody GV20-0251, specifically targeting IGSF8 (Immunoglobulin Superfamily Member 8), also known as EWI-2 or CD316. IGSF8 is a transmembrane glycoprotein that functions as a key regulator of cell adhesion, migration, and signal transduction by associating with tetraspanins such as CD9 and CD81. This protein plays important roles in various physiological processes including sperm-egg fusion, immune cell function, and cancer cell metastasis. IGSF8 expression has been implicated in several pathological conditions, particularly in tumor progression and metastasis, where it influences cancer cell motility and invasiveness across multiple malignancies.
The reference antibody GV20-0251 has been utilized in research investigating IGSF8's molecular interactions and cellular functions. This biosimilar provides researchers with a reliable tool for exploring IGSF8-mediated pathways in cell biology, immunology, and oncology studies. The antibody enables investigation of IGSF8's role in tetraspanin-enriched microdomains and its contribution to cellular processes relevant to cancer research and reproductive biology.
There are currently no reviews for this product.